CD4+ T細胞誘発性炎症性細胞死が免疫逃避性腫瘍を制御する
Bastian Kruse1, Anthony C Buzzai1, Naveen Shridhar1
1Laboratory of Experimental Dermatology, Department of Dermatology, University Hospital and Health Campus Immunology Infectiology and Inflammation (GC-I3), Otto-von-Guericke University, Magdeburg, Germany.
Nature
|June 14, 2023
まとめ
CD4+T細胞は,骨髄細胞を再プログラムすることで,主要な組織相容性複合体 (MHC) 欠乏した腫瘍を排除することができます. この先天的な免疫刺激は,進行したがんの免疫療法における CD8+ T細胞治療を補完します.
科学分野:
- 免疫学
- 癌 生物学
- 細胞免疫学
背景:
- 現在のがん免疫療法では,主にCD8+T細胞が腫瘍細胞を殺害します.
- メジャー・ヒストコンパティビリティ・コンプレックス (MHC) 欠乏症の腫瘍と免疫抑制性腫瘍の微小環境は,現在の免疫療法の有効性を制限する.
- CD4+エフェクターT細胞は,CD8+T細胞とは独立して抗腫瘍免疫の可能性を示しているが,その機能を最大化するための戦略が必要である.
研究 の 目的:
- CD4+ T細胞がMHC欠乏腫瘍を根絶するメカニズムを解明する.
- 癌の免疫療法におけるCD4+ T細胞の潜在能力を最大限活用するための戦略を特定する.
主な方法:
- 腫瘍の縁にある抗原を提示する細胞とのCD4+T細胞の相互作用を調査した.
- Tヘルパー1型細胞に誘導されたCD4+T細胞と先天的な免疫刺激を利用した.
- 腫瘍に関連した骨髄細胞のエフェクタフェノタイプへの再プログラミングを分析した.
主要な成果:
- 少数のCD4+T細胞は,MHC欠乏した腫瘍を根絶するのに十分であった.
- CD4+ T細胞は,MHC- II+CD11c+抗原を提示する細胞と腫瘍侵襲性領域で相互作用した.
- 生まれながらの免疫刺激により,骨髄細胞は,インターフェロン活性化抗原提示細胞およびiNOS発現腫瘍駆除細胞に再プログラムされました.
- CD4+ T細胞と腫瘍殺菌性髄膜細胞は遠隔炎症性細胞死を引き起こし,インターフェロン反応しないおよびMHC欠乏した腫瘍を根絶した.
結論:
- CD4+T細胞は,先天的な免疫刺激剤と併用して,MHC欠乏した腫瘍を排除することができます.
- このメカニズムは既存のがん免疫療法を強化する 補完的な戦略を提供する.
- CD4+T細胞と先天的な免疫刺激剤の臨床利用は,現在の治療法の限界を克服することによって,がん治療を進める可能性があります.
さらに関連する動画
関連する概念動画
Tumor Immunotherapy
575
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
575
Cytotoxic T Cells-mediated Immune Response
999
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
999
T Cell Types and Functions
1.1K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.1K
The Extrinsic Apoptotic Pathway
6.5K
The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
6.5K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K


